Literature DB >> 10727786

Systemic and intra-accumbens administration of amphetamine differentially affects cortical acetylcholine release.

H M Arnold1, C L Nelson, G N Neigh, M Sarter, J P Bruno.   

Abstract

The present experiments tested the hypothesis that the amphetamine-induced increase in dopamine release in the nucleus accumbens represents a necessary and sufficient component of the ability of systemically administered amphetamine to stimulate cortical acetylcholine release. The effects of systemic or intra-accumbens administration of amphetamine on accumbens dopamine release and cortical acetylcholine release were assessed simultaneously in awake animals equipped with dialysis probes inserted into the shell of the nucleus accumbens and the medial prefrontal cortex. Additionally, the ability of intra-accumbens administration of dopamine D(1) and D(2) receptor antagonists to attenuate the effects of systemic amphetamine on cortical acetylcholine was tested. The effects of all treatments were assessed in interaction with a stimulus-induced activation of cortical acetylcholine release to account for the possibility that the demonstration of the trans-synaptic effects of accumbens dopamine requires pre-activation of basal forebrain circuits. Systemic amphetamine resulted in increases in basal cortical acetylcholine and accumbens dopamine efflux. Intra-accumbens administration of amphetamine substantially increased accumbens dopamine efflux, but did not significantly affect cortical acetylcholine efflux. Furthermore, intra-accumbens administration of sulpiride or SCH 23390 did not attenuate the systemic amphetamine-induced increase in cortical acetylcholine efflux. Collectively, the present data suggest that increases in accumbens dopamine release are neither sufficient nor necessary for the effects of systemically administered amphetamine on cortical acetylcholine release. The systemic amphetamine-induced increase in cortical acetylcholine may be mediated via multiple, parallel pathways and may not be attributable to a single afferent pathway of the basal forebrain.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10727786     DOI: 10.1016/s0306-4522(99)00590-4

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  7 in total

Review 1.  Regulation of cortical acetylcholine release: insights from in vivo microdialysis studies.

Authors:  Jim R Fadel
Journal:  Behav Brain Res       Date:  2010-02-16       Impact factor: 3.332

Review 2.  Microdialysis as a tool in local pharmacodynamics.

Authors:  Yanjun Li; Joanna Peris; Li Zhong; Hartmut Derendorf
Journal:  AAPS J       Date:  2006-04-07       Impact factor: 4.009

Review 3.  Modulators in concert for cognition: modulator interactions in the prefrontal cortex.

Authors:  Lisa A Briand; Howard Gritton; William M Howe; Damon A Young; Martin Sarter
Journal:  Prog Neurobiol       Date:  2007-06-30       Impact factor: 11.685

4.  Transient inactivation of the neonatal ventral hippocampus permanently disrupts the mesolimbic regulation of prefrontal cholinergic transmission: implications for schizophrenia.

Authors:  Julie M Brooks; Martin Sarter; John P Bruno
Journal:  Neuropsychopharmacology       Date:  2011-08-03       Impact factor: 7.853

5.  Effects of nucleus accumbens amphetamine administration on performance in a delay discounting task.

Authors:  Caitlin A Orsini; Marci R Mitchell; Sara C Heshmati; Kristy G Shimp; Megan S Spurrell; Jennifer L Bizon; Barry Setlow
Journal:  Behav Brain Res       Date:  2017-01-03       Impact factor: 3.332

6.  D2-like receptors in nucleus accumbens negatively modulate acetylcholine release in prefrontal cortex.

Authors:  Julie M Brooks; Martin Sarter; John P Bruno
Journal:  Neuropharmacology       Date:  2007-06-26       Impact factor: 5.250

7.  Disruption of mesolimbic regulation of prefrontal cholinergic transmission in an animal model of schizophrenia and normalization by chronic clozapine treatment.

Authors:  Kathleen S Alexander; Julie M Brooks; Martin Sarter; John P Bruno
Journal:  Neuropsychopharmacology       Date:  2009-08-19       Impact factor: 7.853

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.